Mitochondrial NAD+ Salvage Enhancement

STING-NAD+ Circuit Modulation for Neuroprotection

Overview

NAD+ (nicotinamide adenine dinucleotide) is a central metabolic cofactor required for energy generation, DNA repair, and cellular signaling in all living cells. In the aging brain, NAD+ levels decline by 30-50%, with particularly severe depletion in neurons and astrocytes. This decline has been linked to mitochondrial dysfunction, increased oxidative stress, impaired DNA repair, and neuronal cell death. A key but underappreciated driver of NAD+ depletion in the aging brain is the activation of STING (Stimulator of Interferon Genes), an innate immune pathway that sequesters and consumes NAD+ as part of its signaling cascade.

STING-NAD+ Circuit Modulation for Neuroprotection

Overview

NAD+ (nicotinamide adenine dinucleotide) is a central metabolic cofactor required for energy generation, DNA repair, and cellular signaling in all living cells. In the aging brain, NAD+ levels decline by 30-50%, with particularly severe depletion in neurons and astrocytes. This decline has been linked to mitochondrial dysfunction, increased oxidative stress, impaired DNA repair, and neuronal cell death. A key but underappreciated driver of NAD+ depletion in the aging brain is the activation of STING (Stimulator of Interferon Genes), an innate immune pathway that sequesters and consumes NAD+ as part of its signaling cascade. This hypothesis proposes that modulating the STING-NAD+ circuit — either by inhibiting STING-mediated NAD+ consumption or by bypassing it through enhanced NAD+ salvage — can restore NAD+ levels in aged neurons, prevent STING-induced senescence, and provide broad neuroprotection.

Mechanistic Basis

STING is a transmembrane protein residing in the endoplasmic reticulum membrane that serves as a central hub for innate immune detection of cytosolic DNA. Activation of STING occurs when cGAS (cyclic GMP-AMP synthase) detects aberrant cytosolic DNA — including mitochondrial DNA released from damaged mitochondria, transposable element DNA that accumulates in aging cells, and fragmented nuclear DNA from dysfunctional nuclei. Upon cGAMP binding, STING undergoes conformational change, translocates from the ER to the Golgi, and activates IRF3 and NF-κB to induce interferon and inflammatory gene expression.

Critically, activated STING directly competes with the NAD+ biosynthesis pathway. STING activation stimulates PARP1 (poly-ADP-ribose polymerase 1) hyperactivation for DNA repair signaling, consuming large quantities of NAD+ precursors. Additionally, STING promotes the induction of CD38, a major NAD+-consuming enzyme, through its inflammatory transcriptional program. This creates a dual mechanism of NAD+ depletion: direct PARP consumption and CD38-mediated hydrolysis. In the aging brain, where mitochondrial DNA release and transposable element activation continuously stimulate STING, these NAD+ consumption pathways operate chronically, creating a state of permanent NAD+ deficiency.

The consequences of STING-driven NAD+ depletion extend beyond energy metabolism. NAD+ is required for the activity of sirtuins (SIRT1-7), which regulate mitochondrial biogenesis (SIRT1, SIRT3), mitophagy (SIRT1), epigenetic regulation (SIRT1, SIRT6), and DNA damage responses (SIRT1, SIRT6). NAD+ depletion impairs sirtuin function, resulting in mitochondrial dysfunction, epigenetic dysregulation, and accumulation of DNA damage — all of which further activate STING, creating a vicious cycle.

Therapeutic Strategy

Multiple strategies can target the STING-NAD+ circuit:

STING Inhibitors: Small molecule STING inhibitors (H-151, MSA-2, various clinical candidates) prevent the initial activation step, blocking downstream NAD+ consumption and inflammatory signaling. Several STING inhibitors have demonstrated CNS penetration and are advancing in clinical development for autoimmune conditions. For neurodegeneration, the key advantage is interrupting the chronic, low-grade STING activation driven by aging-associated mtDNA release.

CD38 Inhibitors: CD38 is the primary NAD+-consuming enzyme in aging tissues, and its expression is induced by STING activation. Small molecule CD38 inhibitors (apigenin, kuromanin, and more potent synthetic compounds) can restore NAD+ levels by reducing the catabolic rate without affecting biosynthesis. CD38 inhibition in aged mice reverses NAD+ decline and improves multiple aging phenotypes.

NAD+ Precursor Supplementation: Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors that bypass the enzymatic bottlenecks in NAD+ biosynthesis. By flooding the salvage pathway, these compounds can overcome STING-mediated consumption and restore NAD+ to youthful levels. Multiple human clinical trials have demonstrated safe and effective NAD+ elevation with NR and NMN supplementation.

PARP1 Inhibition: Selective PARP1 inhibitors approved for cancer therapy (olaparib, niraparib) could be repurposed to reduce STING-stimulated NAD+ consumption. However, PARP1 is required for legitimate DNA repair, so inhibition must be carefully calibrated to preserve repair capacity while preventing the pathological hyperactivation associated with STING signaling.

Combined Approach: The most effective strategy likely combines low-dose STING inhibition to reduce the pathological driver of NAD+ depletion with NAD+ precursor supplementation to rapidly restore baseline levels. This combination can address both the cause (STING activation) and the consequence (NAD+ deficiency) simultaneously.

Evidence Base

Strong preclinical evidence supports STING-NAD+ circuit modulation as a neuroprotective strategy. In aged mice, STING knockout or pharmacological inhibition reduces brain inflammation, improves mitochondrial function in neurons, and enhances cognitive performance on hippocampus-dependent tasks. NAD+ supplementation with NR or NMN in aged rodents reverses multiple age-related phenotypes including reduced dendritic complexity, impaired adult hippocampal neurogenesis, and decreased SIRT1 activity in neurons.

Single-cell transcriptomics of aging mouse brains reveals a population of neurons with co-elevated STING pathway genes and markers of NAD+ deficit (decreased SIRT1 targets, increased PARP activation markers). This senescent-like neuronal subpopulation is enriched in the hippocampus and prefrontal cortex, regions critical for learning and memory. Treatment with STING inhibitors reduces the proportion of cells in this state and improves functional outcomes.

Human genetic data supports this mechanism: variants in ENPP1 (which degrades cGAMP and reduces STING activity) that decrease ENPP1 function are associated with reduced NAD+ metabolite levels and increased risk of age-related cognitive decline in large-scale genetic studies.

Clinical Relevance

NAD+ decline is a hallmark of aging with direct relevance to neurodegeneration. Alzheimer's disease brains show severe NAD+ depletion relative to age-matched controls, and lower NAD+ levels correlate with greater tau burden and cognitive impairment. STING activation is elevated in AD brains and CSF, supporting the model that STING-driven NAD+ consumption contributes to disease progression.

The therapeutic landscape for NAD+ enhancement is already substantial: NR and NMN supplements are widely available and have an established safety profile in humans. STING inhibitors are advancing in clinical trials for inflammatory diseases. Combining existing tools with mechanistic understanding of the STING-NAD+ circuit could enable more targeted and effective interventions than NAD+ supplementation alone.

Predicted Outcomes

Successful STING-NAD+ circuit modulation would be expected to: increase brain NAD+ levels measured by 31P-MRS or CSF metabolomics, reduce STING pathway activation markers (IRF3 phosphorylation, IFN-β, ISG expression in CSF cells), restore sirtuin activity as measured by acetylation status of sirtuin substrates, improve mitochondrial respiratory capacity in neurons, reduce markers of cellular senescence (p21, SA-β-gal), and improve cognitive performance.

Clinical monitoring would include NAD+ and NAD+ metabolite levels in blood and CSF, inflammatory markers (IFN-β, CXCL10 as STING targets), mitochondrial biomarkers (cell-free mtDNA, mitochondrial function assays on PBMCs as surrogate tissue), and cognitive/functional endpoints.

Risk Assessment

Inhibiting STING may impair antiviral responses and tumor surveillance, as STING is required for effective immune responses to DNA viruses and certain tumors. Patient stratification and careful immune monitoring are necessary. For NAD+ precursor approaches, high-dose supplementation can cause flushing, GI discomfort, and potential downstream effects on sirtuin activity that require monitoring. The optimal therapeutic window for STING inhibition in the context of aging rather than acute infection needs careful determination.